Can-Fite BioPharma Ltd. (CANF) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CANF Revenue Growth
CANF Revenue Analysis (2013–2024)
As of May 8, 2026, Can-Fite BioPharma Ltd. (CANF) generated trailing twelve-month (TTM) revenue of $560,000, reflecting significant decline in growth of -36.1% year-over-year. The most recent quarter (Q2 2025) recorded $101,000 in revenue, up 0.0% sequentially.
Looking at the longer-term picture, CANF's 5-year compound annual growth rate (CAGR) stands at -19.8%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $3.8 million in 2018.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), ACAD (+9.9% YoY), and INVA (+13.6% YoY), CANF has underperformed the peer group in terms of revenue growth. Compare CANF vs RCUS →
CANF Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CANFCurrent | $560,000 | -36.1% | -19.8% | -1206.2% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% |
CANF Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $674K | -9.3% | $674K | 100.0% | $-8,130,000 | -1206.2% |
| 2023 | $743K | -8.3% | $743K | 100.0% | $-8,195,000 | -1103.0% |
| 2022 | $810K | -5.0% | $810K | 100.0% | $-10,096,000 | -1246.4% |
| 2021 | $853K | +11.8% | $853K | 100.0% | $-12,842,000 | -1505.5% |
| 2020 | $763K | -62.5% | $763K | 100.0% | $-14,139,000 | -1853.1% |
| 2019 | $2.0M | -46.8% | $2.0M | 100.0% | $-12,007,000 | -590.9% |
| 2018 | $3.8M | +352.2% | $3.8M | 100.0% | $-5,414,000 | -141.7% |
| 2017 | $845K | +398.4% | $845K | 100.0% | $-7,375,705 | -873.1% |
| 2016 | $170K | +2.9% | $170K | 100.0% | $-8,633,858 | -5093.7% |
| 2015 | $165K | - | $165K | 100.0% | $-6,415,005 | -3894.6% |
See CANF's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CANF Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CANF vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCANF — Frequently Asked Questions
Quick answers to the most common questions about buying CANF stock.
Is CANF's revenue growth accelerating or slowing?
CANF revenue declined -36.1% year-over-year, contrasting with the 5-year CAGR of -19.8%. TTM revenue fell to $560000.00. This reverses the prior growth trend.
What is CANF's long-term revenue growth rate?
Can-Fite BioPharma Ltd.'s 5-year revenue CAGR of -19.8% reflects the variable expansion pattern. Current YoY growth of -36.1% is below this long-term average.
How is CANF's revenue distributed by segment?
CANF reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.